Observation On Clinical Efficacy Of Seretide And Symbicort Combined With Tiotropium Bromide In Treating Stable Stage Of Moderate To Severe COPD

ObjectiveTo investigate the clinical efficacy of budesonide/formoterol power inhalation(Symbicort) and salmeterol/fluticasone powder for inhalation(Seretide) combined with Tiotropium bromide in treating the stable stage of moderate to severe COPD Patients.MethodsA total of 60 cases of moderate to severe stable COPD treated in our hospital from January to Decemer 2014 were randomly divided into the Groups A, B and C,20 cases in every group. The group A were treated by Symbicort combined with Tiotropium bromide;The group B by seretide combined with Tiotropium bromide;The group C by Tiotropium bromide.The treatment period was 6months. Then st.George respiratory disease questionnaire(SGRQ) score 、 6minutes walking distance(6-MWD)、 pulmonary function indexes and the acute exacerbation times,spre and post treatment changes were measured in 3 groups.ResultThe living quality,6-MWD and pulmony function after treatment in 3groups were improved,moreover the combined medication was superior to simple medication,Compared with single group,combined groups can reduced the acute exacerbation times significantly, the acute exacerbation times in group A was decreased compared with the group B, the difference was statistically significant(P<0.05).ConclusionThe combined medication is the optimal selection scheme for the stable stage of moderate to severe COPD;The Symbicort combined group can significantly reduce the frequency of acute attack than the Seretide combined group.